TS

Trilok Singh

Director Director DIN 02593542
DIN 02593542 First appointment Apr 2010 Primary industry Chemicals
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Apr 2010
Shareholding value β€’β€’β€’β€’ Premium profile

About Trilok Singh

Data last updated:

Trilok Singh was a Director at Roussel Drugs & Pharmaceuticals Private Limited (2011) and Director at P. D. Next Laboratories Private Limited (2010–2011). The companies operate in Chemicals and Pharma.

DIN 02593542
Primary Designation Director
Industry Chemicals
First Appointment 02 Apr 2010

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director03 May 20112008Strike Off
Director02 Apr 20102009Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Roussel Drugs & Pharmaceuticals Private Limited
P. D. Next Laboratories Private Limited
Premium access

Shareholding and investment profile for Trilok Singh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Trilok Singh

Trilok Singh was first appointed on 02 Apr 2010 as Director at P. D. Next Laboratories Private Limited. The most recent appointment on record is 03 May 2011 at Roussel Drugs & Pharmaceuticals Private Limited.

Trilok Singh held 2 earlier board appointments: Roussel Drugs & Pharmaceuticals Private Limited (Director, 03 May 2011 to 08 Dec 2011); P. D. Next Laboratories Private Limited (Director, 02 Apr 2010 to 08 Dec 2011).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available